Washington, DCThe US Food and Drug Administration is warning health professionals that a certain class of injectable imaging drugs can pose MRI health risks to those with kidney disease.
According to the Associated Press, the FDA will add its strongest warning yet to MRI imaging drugs that contain the chemical gadolinium. The label will warn about the danger the imaging agents can pose to patients with kidney problems.
"These label changes are intended to help ensure these drugs are used appropriately," the FDA said on its website.
Specifically, three types of gadolinium-based contrast agents - Magnevist, Omniscan and Optimark - will be "described as inappropriate for use among patients with acute kidney injury or chronic severe kidney disease," according to the FDA.
Dr. Rafel Rieves, director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research said that the warnings are being added to enhance patient safety.
"The FDA is requiring these labeling changes to enhance the safe use of gadolinium-based contrast agents, including avoidance of certain agents among patients at highest risk for nephrogenic systemic fibrosis," he said.
If you or a loved one have suffered losses in this case, please click the link below and your complaint will be sent to a drugs & medical lawyer who may evaluate your MRI Health Risk claim at no cost or obligation.